Hirobriz Breezhaler (Indacaterol)

Hirobriz Breezhaler is indicated for the long‑term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) to reduce exacerbations and improve lung function.

• As a maintenance bronchodilator for COPD patients with moderate to severe airflow limitation.
• To improve dyspnea and exercise tolerance in stable COPD.
• As part of a comprehensive COPD management plan that may include smoking cessation and pulmonary rehabilitation.
• For patients who require a once‑daily LABA without an inhaled corticosteroid.
• May be used in combination with other COPD maintenance agents such as long‑acting muscarinic antagonists (LAMA) when additional bronchodilation is needed.

• Indacaterol is a selective, long‑acting β2‑adrenergic receptor agonist. After inhalation, it binds to β2 receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing intracellular cyclic AMP. The rise in cAMP leads to protein kinase A activation, which phosphorylates target proteins that cause relaxation of bronchial smooth muscle, resulting in sustained bronchodilation for up to 24 hours. The prolonged receptor occupancy contributes to once‑daily dosing and improves overall lung function in COPD patients.

Adverse reactions reported with Hirobriz Breezhaler are generally consistent with the class of long‑acting β2‑agonists and may affect the respiratory system, cardiovascular system, or other organ systems.

Common

• Cough or throat irritation after inhalation, often mild and transient.
• Dry mouth or oropharyngeal discomfort, sometimes accompanied by a sensation of dryness in the throat.
• Headache, which may be mild to moderate in intensity.
• Nasopharyngitis or upper respiratory tract infection, presenting as nasal congestion, rhinorrhea, or sore throat.

Serious

• Paradoxical bronchospasm, a sudden narrowing of the airways that may require immediate medical evaluation.
• Cardiovascular events such as tachycardia, palpitations, or hypertension, particularly in patients with pre‑existing heart disease.
• Severe hypersensitivity reactions, including rash, angioedema, or anaphylaxis, which necessitate prompt treatment.

Before prescribing Hirobriz Breezhaler, clinicians should evaluate patient history and consider specific safety concerns related to indacaterol therapy.

• Assess for a history of cardiovascular disease, arrhythmias, or uncontrolled hypertension.
• Use caution in patients with a known hypersensitivity to indacaterol or any component of the inhaler.
• Evaluate the risk of paradoxical bronchospasm, especially in individuals with severe airway hyperreactivity.
• Monitor lung function regularly in patients with severe COPD or frequent exacerbations.
• Consider the potential for drug interactions that may increase β‑agonist effects, such as non‑selective β‑blockers.
• Advise patients to rinse the mouth after inhalation to reduce local irritation and the risk of oral candidiasis.

Indacaterol may interact with other medications that affect β‑adrenergic pathways or cardiovascular function, requiring careful review of a patient’s medication list.

Avoid

• Concomitant use with non‑selective β‑blockers, which can diminish bronchodilator efficacy and precipitate bronchospasm.
• Simultaneous administration of monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants, which may increase the risk of cardiovascular side effects.

Use with caution

• Co‑administration with other long‑acting β2‑agonists or short‑acting bronchodilators, as additive β‑agonist effects can raise heart rate and cause tremor.
• Use together with diuretics or antihypertensive agents, monitoring blood pressure and electrolytes for potential changes.
• Combination with inhaled corticosteroids or anticholinergics is common, but clinicians should observe for any unexpected respiratory or systemic reactions.